Study to Enroll 80 Patients Unlikely to Benefit from Venetoclax/Azacitide (Aza/Ven) Therapy in the US and Europe -- SELLAS’ Predictive ...
The automotive EBIT margin came in at 5.3%. Excluding the EUR 1.3 billion depreciation resulting from the PPA of BMW Brilliance Automotive, the EBIT margin reached 6.4% for the year. And that still ...
Study to Enroll 80 Patients Unlikely to Benefit from Venetoclax/Azacitide (Aza/Ven) Therapy in the US and Europe -- SELLAS' Predictive Biomarker and AI Assisted Precision Medicine Models to be Utilize ...
GPGI, Inc. (NYSE:GPGI) Q4 2025 Earnings Call Transcript March 12, 2026 GPGI, Inc. misses on earnings expectations. Reported EPS is $0.23 EPS, expectations were $0.2336. Operator: Good day, and thank ...
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2025 Earnings Call Transcript March 12, 2026 Corvus Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.15451 EPS, expectations ...
Zevra Therapeutics, Inc. is rated a Buy, delivered robust FY25 results, with 350% revenue growth to $106.5M. Learn more about ZVRA stock here.
Reported Promising Data for TN-201 and TN-401 Gene Therapies in Fourth Quarter of 2025; Additional Data Readouts and Pursuit of Regulatory ...
Gulf Business on MSN
Food on the move: How Careem, talabat and noon are keeping UAE orders moving
For millions of residents in the UAE, ordering food or groceries through a smartphone app remains a routine part of daily life ...
Strong enrollment momentum in Phase 1 autoimmune program evaluating prulacabtagene leucel (prula-cel, formerly ADI-001); clinical update expected in 1H/2026 with an additional update in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results